Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Design and preparation of .

Journal of materials chemistry. B

Radović M, Mirković M, Perić M, Janković D, Vukadinović A, Stanković D, Petrović Đ, Bošković M, Antić B, Marković M, Vranješ-Đurić S.
PMID: 32264267
J Mater Chem B. 2017 Nov 28;5(44):8738-8747. doi: 10.1039/c7tb02075a. Epub 2017 Oct 27.

Radiolabeled magnetic nanoparticles (MNPs) coated with hydrophilic phosphate ligands, i.e., imidodiphosphate (IDP) and inositol hexaphosphate (IHP), were developed as multifunctional agents to localize both radioactivity and magnetic energy at a tumor site. The coating of MNPs with phosphates made...

Cite
Radović M, Mirković M, Perić M, et al. Design and preparation of . J Mater Chem B. 2017;5(44):8738-8747doi: 10.1039/c7tb02075a.
Radović, M., Mirković, M., Perić, M., Janković, D., Vukadinović, A., Stanković, D., Petrović, �. �., Bošković, M., Antić, B., Marković, M., & Vranješ-Đurić, S. (2017). Design and preparation of . Journal of materials chemistry. B, 5(44), 8738-8747. https://doi.org/10.1039/c7tb02075a
Radović, Magdalena, et al. "Design and preparation of ." Journal of materials chemistry. B vol. 5,44 (2017): 8738-8747. doi: https://doi.org/10.1039/c7tb02075a
Radović M, Mirković M, Perić M, Janković D, Vukadinović A, Stanković D, Petrović Đ, Bošković M, Antić B, Marković M, Vranješ-Đurić S. Design and preparation of . J Mater Chem B. 2017 Nov 28;5(44):8738-8747. doi: 10.1039/c7tb02075a. Epub 2017 Oct 27. PMID: 32264267.
Copy Download .nbib Format: NLM
Monoclonal Antibodies as Neurological Therapeutics.

Pharmaceuticals (Basel, Switzerland)

Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D.
PMID: 33530460
Pharmaceuticals (Basel). 2021 Jan 26;14(2). doi: 10.3390/ph14020092.

Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including multiple...

Cite
Gklinos P, Papadopoulou M, Stanulovic V, et al. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel). 2021;14(2)doi: 10.3390/ph14020092.
Gklinos, P., Papadopoulou, M., Stanulovic, V., Mitsikostas, D. D., & Papadopoulos, D. (2021). Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel, Switzerland), 14(2), . https://doi.org/10.3390/ph14020092
Gklinos, Panagiotis, et al. "Monoclonal Antibodies as Neurological Therapeutics." Pharmaceuticals (Basel, Switzerland) vol. 14,2 (2021). doi: https://doi.org/10.3390/ph14020092
Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel). 2021 Jan 26;14(2). doi: 10.3390/ph14020092. PMID: 33530460; PMCID: PMC7912592.
Copy Download .nbib Format: NLM
[No title available]

International journal of radiation biology

Milanović Z, Janković D, Vranješ-Đurić S, Radović M, Prijović Ž, Zavišić G, Perić M, Stanković D, Mirković M.
PMID: 34473599
Int J Radiat Biol. 2021;97(12):1687-1695. doi: 10.1080/09553002.2021.1976864. Epub 2021 Sep 20.

PURPOSE: Recent studies with doxycycline as adjuvant therapy to conventional chemotherapy have shown promising results in cancer therapy. The current study aimed to examine the capability of MATERIALS AND METHODS: Doxycycline was radiolabeled with beta-emitting radioisotope RESULTS: Doxycycline hyclate...

Cite
Milanović Z, Janković D, Vranješ-Đurić S, et al. . Int J Radiat Biol. 2021;97(12):1687-1695doi: 10.1080/09553002.2021.1976864.
Milanović, Z., Janković, D., Vranješ-Đurić, S., Radović, M., Prijović, �. �., Zavišić, G., Perić, M., Stanković, D., & Mirković, M. (2021). . International journal of radiation biology, 97(12), 1687-1695. https://doi.org/10.1080/09553002.2021.1976864
Milanović, Zorana, et al. "." International journal of radiation biology vol. 97,12 (2021): 1687-1695. doi: https://doi.org/10.1080/09553002.2021.1976864
Milanović Z, Janković D, Vranješ-Đurić S, Radović M, Prijović Ž, Zavišić G, Perić M, Stanković D, Mirković M. . Int J Radiat Biol. 2021;97(12):1687-1695. doi: 10.1080/09553002.2021.1976864. Epub 2021 Sep 20. PMID: 34473599.
Copy Download .nbib Format: NLM
Routing with Face Traversal and Auctions Algorithms for Task Allocation in WSRN.

Sensors (Basel, Switzerland)

Stanulovic J, Mitton N, Mezei I.
PMID: 34577357
Sensors (Basel). 2021 Sep 13;21(18). doi: 10.3390/s21186149.

Four new algorithms (RFTA1, RFTA2, GFGF2A, and RFTA2GE) handling the event in wireless sensor and robot networks based on the greedy-face-greedy (GFG) routing extended with auctions are proposed in this paper. In this paper, we assume that all robots...

Cite
Stanulovic J, Mitton N, Mezei I. Routing with Face Traversal and Auctions Algorithms for Task Allocation in WSRN. Sensors (Basel). 2021;21(18)doi: 10.3390/s21186149.
Stanulovic, J., Mitton, N., & Mezei, I. (2021). Routing with Face Traversal and Auctions Algorithms for Task Allocation in WSRN. Sensors (Basel, Switzerland), 21(18), . https://doi.org/10.3390/s21186149
Stanulovic, Jelena, et al. "Routing with Face Traversal and Auctions Algorithms for Task Allocation in WSRN." Sensors (Basel, Switzerland) vol. 21,18 (2021). doi: https://doi.org/10.3390/s21186149
Stanulovic J, Mitton N, Mezei I. Routing with Face Traversal and Auctions Algorithms for Task Allocation in WSRN. Sensors (Basel). 2021 Sep 13;21(18). doi: 10.3390/s21186149. PMID: 34577357; PMCID: PMC8472648.
Copy Download .nbib Format: NLM
Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies.

British journal of clinical pharmacology

Stanulović V, Hodolic M, Mitsikostas DD, Papadopoulos D.
PMID: 34342031
Br J Clin Pharmacol. 2021 Aug 02; doi: 10.1111/bcp.15016. Epub 2021 Aug 02.

AIMS: Drug tolerability refers to the degree to which drugs' overt adverse effects can be tolerated by patients. The tolerability profile is of comparative importance to its efficacy and safety, as it largely determines adherence to treatment and ultimately...

Cite
Stanulović V, Hodolic M, Mitsikostas DD, et al. Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.15016.
Stanulović, V., Hodolic, M., Mitsikostas, D. D., & Papadopoulos, D. (2021). Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.15016
Stanulović, Vid, et al. "Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.15016
Stanulović V, Hodolic M, Mitsikostas DD, Papadopoulos D. Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Br J Clin Pharmacol. 2021 Aug 02; doi: 10.1111/bcp.15016. Epub 2021 Aug 02. PMID: 34342031.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries